CLINICAL TRIAL: OGF & GEMCITABINE: NOVEL TREATMENT FOR PANCREATIC CANCER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该方案的主要目的是评估OGF生物治疗和吉西他滨化疗联合的安全性和毒性。这一目的是为了测试OGF和吉西他滨联合治疗的安全性和毒性。此外，还将评估与标准化疗(吉西他滨)单独治疗相比，OGF生物疗法和吉西他滨化疗对晚期胰腺癌患者病情进展时间的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this protocol is to evaluate the safety and toxicity of the combination of OGF biotherapy and gemcitabine chemotherapy. The purpose of this objective is to test the safety and toxicity of the combination treatments OGF and gemcitabine. Additionally , the efficacy of OGF biotherapy and gemcitabine chemotherapy on time to progression of disease in patients with advanced pancreatic cancer compared with those treated with standard chemotherapy (gemcitabine) alone will be evaluated.